Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Pharmacokinetics of AG-2034 examined in patients; results reported at ASCO meeting

May 18, 1999

U.S. university research team designs potent and selective inhibitors of PGGTase-I

May 18, 1999

Synthetic histone deacetylase inhibitor with potent antitumor effects developed in Japan

May 18, 1999

Rebeccamycin analogue NSC-655649 evaluated in adult and pediatric cancer patients

May 18, 1999

News from ASCO: Lutrin is safe and effective in treating locally recurrent breast cancer

May 18, 1999

ZD-0473 exhibits favorable toxicity profile in phase I studies in solid tumor patients

May 17, 1999

News from ASCO: clinical pharmacology of Bay-12-9566 assessed in cancer patients

May 17, 1999

Novel intranasally administered small peptide shows good efficacy and safety in AIDS-related KS

May 17, 1999

Novartis presents first clinical results for Abl tyrosine kinase inhibitor CGP-57148

May 17, 1999

Introgen Therapeutics and RPR Gencell sign CRADA with NCI

May 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.